<DOC>
	<DOCNO>NCT01259713</DOCNO>
	<brief_summary>The study aim investigate whether prophylaxis liposomal amphotericin B ( AmBisome® ) reduce incidence invasive fungal infection ( IFIs ) patient Acute Lymphoblastic Leukemia ( ALL ) undergo first remission induction .</brief_summary>
	<brief_title>Prevention Invasive Fungal Infections ( IFIs ) Subjects Receiving Chemotherapy Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Newly diagnose ALL receive ALL chemotherapy regimen typically induces least 10 day neutropenia define absolute neutrophil count &lt; 500 cells/mm^3 0.5 × 10^9 cells/L Subjects lymphoblastic lymphoma malignancy ALL NOT eligible study . Age ≥ 18 year Able screening test perform quickly ensure result obtain evaluated randomization first dose randomized study drug IFI prophylaxis administer within 5 day first remissioninduction chemotherapy Preremission induction treatment ( ie , prephase ) minimally nonmyelosuppressive regimen one week consider constitute begin remission induction chemotherapy Ability understand sign write informed consent form , must obtain prior initiation study procedure Known hypersensitivity amphotericin B AmBisome , metabolites formulation excipients , particular know history anaphylactic reaction amphotericin B AmBisome metabolites formulation excipients Known hypersensitivity excipients placebo formulation Current fever ( ≥ 38°C ) unless explain noninfectious cause Subjects proven , probable possible IFI ( accord European Organization Research Treatment Cancer/Mycoses Study Group ( EORTC/MSG ) criterion ) screen subject history Pulmonary infiltrate Concomitant previous treatment antifungal drug within previous 30 day unless plasma level limit detection least 5 halflives antifungal elapse since treatment give Serum creatinine &gt; 2 × upper limit normal range ( ULN ) Grade 3 Liver function test result : alanine aminotransferase aspartate aminotransferase &gt; 5 × ULN ; total bilirubin &gt; 2.5 x ULN Any severe co morbidity underlie hematological disease ( ALL ) , investigator 's judgment may interfere study evaluation affect subject 's safety Subjects take investigational drug last 30 day prior screen , exception ALL chemotherapy investigational product use part subject 's current ALL treatment protocol Pregnant nursing female Subjects prior history malignancy treat myeloablative chemotherapy regimen NOT eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Ambisome</keyword>
	<keyword>ALL</keyword>
	<keyword>invasive fungal infection</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>liposomal amphotericin B</keyword>
	<keyword>Invasive fungal infection prophylaxis</keyword>
</DOC>